Related Experiment Videos

Evidence-based management of coronary artery disease in the elderly--current perspectives

Nanette Kass Wenger1, Tarek Helmy, Amar D Patel

  • 1Grady Memorial Hospital, Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.

Medgenmed : Medscape General Medicine
|December 22, 2005
PubMed

Insights

Elderly cardiovascular disease management benefits from ACE inhibitors and lipid-lowering therapy for stable angina. Revascularization is key for severe symptoms, with glycoprotein inhibitors improving outcomes in acute coronary syndromes.

Area of Science:

  • Cardiology
  • Geriatric Medicine
  • Clinical Trials

Background:

  • Cardiovascular disease (CVD) is a major cause of death and illness in older adults.
  • Limited clinical trial data specifically guides CVD therapy in the elderly population.
  • This review examines evidence from subgroup analyses in elderly patients for various cardiovascular conditions.

Purpose of the Study:

  • To review treatment approaches for chronic stable angina, acute coronary syndromes, and coronary revascularization in the elderly.
  • To synthesize recommendations from major clinical trials focusing on elderly patient subgroups.
  • To highlight evidence-based strategies for managing cardiovascular disease in older individuals.

Main Methods:

  • Analysis of subgroup data from major clinical trials involving elderly patients.
  • Focus on chronic stable angina, acute coronary syndromes (unstable angina, NSTEMI), and coronary revascularization.
  • Review of treatment recommendations and outcomes.

Main Results:

  • Angiotensin-converting enzyme inhibitors and lipid-lowering therapy reduce adverse events in elderly patients with stable angina.
  • Coronary revascularization is indicated for disabling or unstable anginal symptoms despite medical therapy.
  • Intravenous glycoprotein receptor antagonists periprocedurally reduce major adverse cardiac events in elderly patients undergoing percutaneous revascularization for ACS.

Conclusions:

  • Adjunctive medical therapies improve outcomes for stable angina in the elderly.
  • Coronary revascularization is a critical option for refractory angina.
  • Periprocedural glycoprotein inhibitors enhance outcomes for elderly patients with ACS undergoing revascularization, with prompt intervention being crucial.
  • Comorbidities significantly impact revascularization success, particularly in those over 80.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...